Nov 7 (Reuters) - Avalo Therapeutics Inc AVTX.O:
AVALO REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND RECENT BUSINESS UPDATES
AVALO THERAPEUTICS: CASH AND CASH EQUIVALENTS WERE $81.9 MILLION AS OF SEPTEMBER 30, 2024
Source text: ID:nGNX9XBMm5
Further company coverage: AVTX.O
((Reuters.Briefs@thomsonreuters.com;))